VSee Health stock rocketed higher Tuesday morning. The company received FedRAMP High authorization from the U.S. Department of Health and Human Services.
Shares jumped 125% in premarket trading on the news. The certification represents the highest level of federal security compliance for cloud-based services.
VSee Health, Inc., VSEE
FedRAMP High authorization means federal agencies can use VSee’s telehealth platform for sensitive healthcare applications. No additional security vetting is required from individual departments.
The platform offers enterprise-grade encryption and HIPAA compliance. It includes healthcare information exchange interoperability and rapid multi-site activation capabilities.
Federal agencies including the Department of Defense, Veterans Affairs, and CDC can now adopt the technology. The authorization removes procurement barriers that previously blocked government contracts.
VSee demonstrated its system during a July emergency situation. A cyberattack disabled IT systems at Governor Juan F. Luis Hospital in St. Croix, U.S. Virgin Islands.
The company deployed a secure telemedicine system for HHS Assistant Secretary for Preparedness and Response. The solution maintained hospital operations throughout the crisis.
VSee’s platform processed over 250 backlogged radiology studies within days. Emergency services continued without interruption during the incident.
This real-world deployment likely influenced the FedRAMP High decision. It showed VSee could handle critical healthcare situations under pressure.
The company is developing AIMEE, focused on rural hospital transformation. The initiative uses AI-enabled digital health infrastructure for improved healthcare sustainability.
VSee announced several developments in October. On October 21, the company revealed a multi-year teleradiology contract exceeding $10 million.
The hospital system deal will double annual recurring revenue. Performance targets could add another $5 million to the contract value.
VSee eliminated over $5 million in legacy debt two days later. The SPAC merger debt removal strengthens the balance sheet and supports NASDAQ compliance.
The company previously received a delisting notice for falling below financial requirements. VSee was granted an extension to address the compliance issues.
Q2 2025 results showed $3.4 million in revenue, up 98% year-over-year. Gross margins improved to approximately 47% for the quarter.
The company remains unprofitable despite revenue growth. Net losses continue as cash burn remains a concern for investors.
Trading activity exploded following the FedRAMP announcement. Over 156 million shares traded compared to typical daily volume under 2 million.
The stock’s 52-week range spans $0.46 to $3.54. This reflects volatility common among micro-cap penny stocks.
Analyst coverage remains limited for the company. One analyst issued a “Strong Buy” rating with a $5.00 price target.
An AI-driven model rates VSee “Underperform” with a $0.50 target. The model points to financial instability and potential delisting risk.
VSee’s market capitalization sits around $10-15 million after the surge. The telehealth sector is projected to grow 20-25% annually through 2035.
The company now holds credentials that differentiate it from competitors. FedRAMP High status validates security for mission-critical government applications.
VSee can pursue contracts previously unavailable to the platform. Federal healthcare workloads requiring top-tier security clearance are now accessible markets.
The post VSee Health (VSEE) Stock Soars as Telehealth Platform Gets Federal Security Approval appeared first on Blockonomi.


